Clinical trial · Interventional
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors
NCT00687934CI-TRIAL-00015649completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STA-9090 | Drug | Ganetespib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ganetespib
- description
- Ganetespib once weekly infusion, dose escalation study, with treatment until progression
- interventionNames
- Drug: STA-9090
Primary outcomes (1)
- measure
- The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities
- timeFrame
- Cycle 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be documented to be refractory or not candidates for current approved therapies. * Must have an ECOG status 0-2. * Peripheral neuropathy \< or = 2. * Must have acceptable organ and marrow function per protocol parameters. * No clinically significant ventricular arrythmias or ischemia. Exclusion Criteria: * Must not be pregnant or breastfeeding. * Chemotherapy or radiation within 3 weeks. * Previous radiation to \>25% of total bone marrow. * Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation. * Primary brain tumors or active brain metastases. * Use of any investigational agents within 4 weeks. * Treatment with chronic immunosuppressants. * Uncontrolled, intercurrent illness.
References
Publications (1)
- DERIVEDGoldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013 Mar 25;13:152. doi: 10.1186/1471-2407-13-152. PMID 23530663